Ocugen (FRA:2H51) Cyclically Adjusted PB Ratio: (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2H51 Ocugen Inc FRA:2H51
20 GF Score
Price €1.17
GF Value €0.70
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocugen Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ocugen  (FRA:2H51) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ocugen Cyclically Adjusted PB Ratio Related Terms


Ocugen Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Ocugen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocugen Cyclically Adjusted PB Ratio Chart

Ocugen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.03 0.03 0.50

Ocugen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.23 0.50 0.00 0.00

FRA:2H51 vs EVMN, PBYI, LRMR: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Ocugen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ocugen's Cyclically Adjusted PB Ratio falls into.


FRA:2H51
20GF Score
Ocugen Inc FRA:2H51
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocugen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ocugen's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Ocugen's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.042/333.9520*333.9520
=-0.042

Current CPI (Jun. 2026) = 333.9520.

Ocugen Quarterly Data

Book Value per Share CPI Adj_Book
201609 13.570 241.428 18.771
201612 37.390 241.432 51.718
201703 17.667 243.801 24.200
201706 1.933 244.955 2.635
201709 -10.626 246.819 -14.377
201712 -23.222 246.524 -31.458
201803 -34.052 249.554 -45.568
201806 -41.798 251.989 -55.393
201809 -14.223 252.439 -18.816
201812 -0.390 251.233 -0.518
201903 -3.105 254.202 -4.079
201906 -4.900 256.143 -6.388
201909 -1.187 256.759 -1.544
201912 0.188 256.974 0.244
202003 0.125 258.115 0.162
202006 0.096 257.797 0.124
202009 0.076 260.280 0.098
202012 0.096 260.474 0.123
202103 0.208 264.877 0.262
202106 0.486 271.696 0.597
202109 0.458 274.310 0.558
202112 0.425 278.802 0.509
202203 0.552 287.504 0.641
202206 0.499 296.311 0.562
202209 0.444 296.808 0.500
202212 0.315 296.797 0.354
202303 0.313 301.836 0.346
202306 0.253 305.109 0.277
202309 0.213 307.789 0.231
202312 0.145 306.746 0.158
202403 0.108 312.332 0.115
202406 0.061 314.175 0.065
202409 0.126 315.301 0.133
202412 0.097 315.605 0.103
202503 0.050 319.799 0.052
202506 0.009 322.561 0.009
202509 0.010 324.800 0.010
202512 -0.033 324.054 -0.034
202603 0.015 330.213 0.015
202606 -0.042 333.952 -0.042

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Ocugen (FRA:2H51) Overvalued in 2026?

Based on GuruFocus' analysis, Ocugen stock appears to be overvalued. The current stock price of €1.17 is trading 66.6% above its estimated GF Value™ of €0.70. GuruFocus considers Ocugen to be Significantly Overvalued.

Key valuation signals for FRA:2H51:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €0.70 vs. price of €1.17 (66.6% above fair value)
  • GF Score™: 20/100 with 4 warning signs

No single metric tells the full story. See the FRA:2H51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocugen Business Description

Address 11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
20GF Score

Get the complete analysis for FRA:2H51

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.17
Price
€0.70
GF Value